Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.32 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.32 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.32 |
| ▸ | WDR5 | P61964 | 6/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.31 |
| ▸ | MAP3K12 | Q12852 | 3/20 | 0.30 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.30 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23760693 | 0.80 | TLR9 (0.51) | TLR7TLR9TLR8 | |
| SCHEMBL23760669 | 0.75 | NOTUM (0.39) | NCF1TLR7TLR9TLR8 | |
| SCHEMBL23628752 | 0.73 | TLR9 (0.41) | MAPK1TLR7TLR9TLR8 | |
| SCHEMBL23760700 | 0.73 | CYP2D6 (0.38) | NCF1MAPK1 | |
| SCHEMBL23628763 | 0.73 | CYP2D6 (0.38) | NCF1MAPK1 | |
| SCHEMBL23628766 | 0.73 | CYP2D6 (0.38) | NCF1MAPK1 | |
| SCHEMBL23628767 | 0.73 | CYP2D6 (0.38) | NCF1MAPK1 | |
| SCHEMBL23628743 | 0.70 | HRH3 (0.38) | — | |
| SCHEMBL23628747 | 0.70 | HRH3 (0.38) | — | |
| SCHEMBL20670317 | 0.69 | PIM2 (0.36) | NCF1TLR7TLR9TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN-LA ROCHE INC. (US) | 2021-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253575-A1 | PYRROLIDINE AMINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | ARG1, PRMT1, PADI1 | NCF1 710/4885MAPK1 1644/4885TLR7 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.